MDACC Study No:CALGB30610-RTOG0538 ( NCT No: NCT00632853)
Title:Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Principal Investigator:Ritsuko R. Komaki
Treatment Agent:Cisplatin; Etoposide; Radiation
Study Status:Open
Study Description:The goal of this clinical research study is to compare the effectiveness and
safety of 2 different ways to give radiation therapy (1 experimental, 1
standard) in combination with chemotherapy to patients with small-cell lung
cancer. The safety of these therapies and their effects on your quality of
life will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase III
Treatment Agents:Cisplatin
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:n/a
Supported By:Cancer and Leukemia Group B (CALGB)
Return Visit: Every 3 months for 2 years, every 6 months for 3 years, then at least every
year for 5 years.
Home Care:n/a

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ritsuko R. Komaki
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults